Related Experiment Video
Updated: Jun 1, 2026
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
Small molecule CXCR3 antagonist NIBR2130 has only a limited impact on type 1 diabetes in a virus-induced mouse model
S Christen1, M Holdener, C Beerli
1Pharmazentrum Frankfurt/ZAFES, Klinikum der Goethe Universität, Frankfurt am Main, Germany. christen@med.uni-frankfurt.de
Abstract:
CXCL10 is one of the key chemokines involved in trafficking of autoaggressive T cells to the islets of Langerhans during the autoimmune destruction of beta cells in type 1 diabetes (T1D). Blockade of CXCL10 or genetic deletion of its receptor CXCR3 results in a reduction of T1D in animal models. As an alternative to the use of neutralizing monoclonal antibodies to CXCL10 or CXCR3 we evaluated the small molecule CXCR3 antagonist NIBR2130 in a virus-induced mouse model for T1D. We found that the overall frequency of T1D was not reduced in mice administered with NIBR2130. An initial slight delay of diabetes onset was not stable over time, because the mice turned diabetic upon removal of the antagonist. Accordingly, no significant differences were found in the islet infiltration rate and the frequency and activity of islet antigen-specific T cells between protected mice administered with NIBR2130 and control mice. Our data indicate that in contrast to direct inhibition of CXCL10, blockade of CXCR3 with the small molecule antagonist NIBR2130 has no impact on trafficking and/or activation of autoaggressive T cells and is not sufficient to prevent T1D.
Insights
Small molecule CXCR3 antagonist NIBR2130 did not prevent type 1 diabetes (T1D) in mice. Blocking CXCR3 with NIBR2130 did not impact T cell trafficking or activation, unlike CXCL10 inhibition.
Area of Science:
- Immunology
- Endocrinology
- Virology
Background:
- CXCL10 chemokine is crucial for T cell trafficking to pancreatic islets in type 1 diabetes (T1D).
- Blocking CXCL10 or its receptor CXCR3 reduces T1D incidence in animal models.
- Small molecule antagonists offer an alternative to antibody-based therapies for T1D.
Purpose of the Study:
- To evaluate the efficacy of the small molecule CXCR3 antagonist NIBR2130 in preventing T1D.
- To assess the impact of CXCR3 blockade on autoaggressive T cell trafficking and activation in a virus-induced T1D mouse model.
Main Methods:
- Administration of NIBR2130 in a virus-induced mouse model of T1D.
- Monitoring of T1D onset and progression.
- Analysis of islet infiltration, T cell frequency, and activity.
Main Results:
- NIBR2130 did not reduce the overall frequency of T1D.
- A transient delay in diabetes onset was observed, but T1D developed upon antagonist removal.
- No significant differences in islet infiltration or T cell responses were found between NIBR2130-treated and control groups.
Conclusions:
- CXCR3 blockade with NIBR2130 is insufficient to prevent T1D.
- Unlike CXCL10 inhibition, NIBR2130 did not affect autoaggressive T cell trafficking or activation.
- Small molecule CXCR3 antagonists may not be effective for T1D prevention.
